• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD59(同源限制因子20),一种存在于人类动脉粥样硬化病变中、可抵御补体C5b-9攻击的质膜蛋白。

CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions.

作者信息

Seifert P S, Roth I, Schmiedt W, Oelert H, Okada N, Okada H, Bhakdi S

机构信息

Institute for Medical Microbiology, Johannes Gutenberg University, Mainz, FRG.

出版信息

Atherosclerosis. 1992 Oct;96(2-3):135-45. doi: 10.1016/0021-9150(92)90060-t.

DOI:10.1016/0021-9150(92)90060-t
PMID:1281630
Abstract

Blood cells express a cell membrane protein, termed homologous restriction factor 20 (HRF20) and identical to CD59, that can inhibit complement C5b-9 insertion into their membranes. In this report, we investigated by immunohistochemistry whether CD59 was present on cells in human atherosclerotic lesions since membranous C5b-9(m) has been found in lesions. Using a monoclonal anti-CD59 antibody, a cellular CD59 staining pattern was apparent in nearly all lesion specimens. CD59 stain co-localised with macrophage (CD14), T lymphocyte (CD7), endothelial cell (anti-factor VIII related antigen) and smooth muscle cell cytoskeletal-specific antigens (anti-alpha actin and muscle myosin). Endothelial cells always exhibited a more intense stain than the other cell types. CD59 antigen was not localised to any one area of the lesions. Usually CD59-positive cells occurred in clusters rather than as randomly spaced individual cells. CD59 did not stain all cells of the lesion and in particular did not appear to stain all smooth muscle cells. Areas of CD59-negative cells were sometimes observed to exhibit a cellular C5b-9 staining pattern. C5b-9 deposits were also observed in CD59-positive regions. Normal saphenous vein stained strongly for CD59 at the endothelial lining and weakly in the media. Capillaries in atherosclerotic intima always stained strongly for CD59. We conclude that HRF20 is constitutively expressed on endothelium and is under regulatory control in smooth muscle cells. Cellular C5b-9 attack in atherosclerotic lesions is therefore most likely to occur on smooth muscle cells.

摘要

血细胞表达一种细胞膜蛋白,称为同源限制因子20(HRF20),与CD59相同,它能抑制补体C5b - 9插入其细胞膜。在本报告中,我们采用免疫组织化学方法研究了人动脉粥样硬化病变细胞中是否存在CD59,因为在病变中已发现膜性C5b - 9(m)。使用单克隆抗CD59抗体,在几乎所有病变标本中都出现了细胞CD59染色模式。CD59染色与巨噬细胞(CD14)、T淋巴细胞(CD7)、内皮细胞(抗因子VIII相关抗原)和平滑肌细胞细胞骨架特异性抗原(抗α - 肌动蛋白和肌球蛋白)共定位。内皮细胞的染色总是比其他细胞类型更强烈。CD59抗原并不局限于病变的任何一个区域。通常CD59阳性细胞成簇出现,而不是随机分布的单个细胞。CD59并未对病变中的所有细胞染色,尤其似乎并未对所有平滑肌细胞染色。有时观察到CD59阴性细胞区域呈现细胞C5b - 9染色模式。在CD59阳性区域也观察到了C5b - 9沉积物。正常大隐静脉在内皮衬里处CD59染色强烈,在中膜处染色较弱。动脉粥样硬化内膜中的毛细血管CD59染色总是很强。我们得出结论,HRF20在内皮细胞上组成性表达,在平滑肌细胞中受调控。因此,动脉粥样硬化病变中的细胞C5b - 9攻击最有可能发生在平滑肌细胞上。

相似文献

1
CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions.CD59(同源限制因子20),一种存在于人类动脉粥样硬化病变中、可抵御补体C5b-9攻击的质膜蛋白。
Atherosclerosis. 1992 Oct;96(2-3):135-45. doi: 10.1016/0021-9150(92)90060-t.
2
Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).人类癌症会不同程度地表达补体抑制蛋白CD46(膜辅因子蛋白)、CD55(衰变加速因子)和CD59(保护素)。
Am J Pathol. 1996 Jul;149(1):129-42.
3
Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions.
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2448-52. doi: 10.1161/01.atv.17.11.2448.
4
C5b-8 step lysis of swine endothelial cells by human complement and functional feature of transfected CD59.人补体对猪内皮细胞的C5b-8级联溶解作用及转染CD59的功能特性
Scand J Immunol. 1996 Apr;43(4):361-6. doi: 10.1046/j.1365-3083.1996.d01-50.x.
5
Distribution of complement regulatory proteins, decay-accelerating factor, CD59/homologous restriction factor 20 and membrane cofactor protein in human colorectal adenoma and cancer.补体调节蛋白、衰变加速因子、CD59/同源限制因子20和膜辅助因子蛋白在人大肠腺瘤和癌中的分布
Acta Med Okayama. 1994 Oct;48(5):271-7. doi: 10.18926/AMO/31112.
6
Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59.人内皮细胞表面末端补体蛋白的调节控制:抗CD59抗体对C5b - 9抑制剂的中和作用
Blood. 1990 Dec 15;76(12):2572-7.
7
Protection of thyroid cancer cells by complement-regulatory factors.补体调节因子对甲状腺癌细胞的保护作用。
Cancer. 1994 Jun 1;73(11):2808-17. doi: 10.1002/1097-0142(19940601)73:11<2808::aid-cncr2820731125>3.0.co;2-p.
8
Localization of the complement regulatory proteins in the normal human kidney.补体调节蛋白在正常人体肾脏中的定位。
Kidney Int. 1994 Jul;46(1):89-96. doi: 10.1038/ki.1994.247.
9
A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.一种来自补体蛋白C9的合成肽与CD59结合,并增强C5b-9对人红细胞的裂解作用。
J Immunol. 1994 Feb 15;152(4):1927-34.
10
Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.CD59对同源补体的抑制作用是通过与C5b-8中的C8或C5b-9中的C9结合所赋予的物种选择性识别来介导的。
J Immunol. 1991 Apr 1;146(7):2345-51.

引用本文的文献

1
Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers.用于双重靶向肿瘤相关内皮细胞和基质中巨噬细胞的多孔硅纳米载体用于原位人胰腺癌细胞。
Cancer Lett. 2013 Jul 1;334(2):319-27. doi: 10.1016/j.canlet.2012.09.001. Epub 2012 Sep 18.
2
Identification of a novel short peptide seal specific to CD59 and its effect on HeLa cell growth and apoptosis.鉴定一种针对 CD59 的新型短肽封条及其对 HeLa 细胞生长和凋亡的影响。
Cell Oncol (Dordr). 2012 Oct;35(5):355-65. doi: 10.1007/s13402-012-0096-2. Epub 2012 Sep 4.
3
Lack of complement inhibitors in the outer intracranial artery aneurysm wall associates with complement terminal pathway activation.
颅内动脉壁缺乏补体抑制剂与补体末端途径激活有关。
Am J Pathol. 2010 Dec;177(6):3224-32. doi: 10.2353/ajpath.2010.091172. Epub 2010 Oct 22.
4
Anticomplement therapy.抗补体疗法。
Biologics. 2008 Dec;2(4):671-85. doi: 10.2147/btt.s2753.
5
Inflammatory proteins on HDL: what are we measuring?高密度脂蛋白上的炎症蛋白:我们在测量什么?
Transl Res. 2007 Sep;150(3):150-2. doi: 10.1016/j.trsl.2007.04.007. Epub 2007 May 21.
6
The role of complement activation in atherosclerosis.补体激活在动脉粥样硬化中的作用。
Immunol Res. 2004;30(1):73-80. doi: 10.1385/IR:30:1:073.
7
Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane.急性和慢性关节炎中的补体:滑膜中C3c、C9和膜攻击复合物抑制因子(CD59)的评估
Ann Rheum Dis. 1996 Dec;55(12):888-94. doi: 10.1136/ard.55.12.888.
8
Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the possible implication in the atherosclerosis.高密度脂蛋白缺乏症(丹吉尔病)患者血清补体活性升高:簇集素水平正常及其在动脉粥样硬化中的可能意义。
Clin Exp Immunol. 1993 Aug;93(2):242-7. doi: 10.1111/j.1365-2249.1993.tb07973.x.